Abstract
Over the last few years, huge progress has been made with regard to the understanding of molecular mechanisms underlying the pathogenesis of neurodegenerative diseases of the eye. Such knowledge has led to the development of gene therapy approaches to treat these devastating disorders. Challenges regarding the efficacy and efficiency of therapeutic gene delivery have driven the development of novel therapeutic approaches, which continue to evolve the field of ocular gene therapy. In this review article, we will discuss the evolution of preclinical and clinical strategies that have improved gene therapy in the eye, showing that treatment of vision loss has a bright future.Source
Hum Gene Ther. 2016 Aug;27(8):563-79. doi: 10.1089/hum.2016.040. Epub 2016 Jun 13. Link to article on publisher's siteDOI
10.1089/hum.2016.040Permanent Link to this Item
http://hdl.handle.net/20.500.14038/36668PubMed ID
27178388Related Resources
Link to Article in PubMedRights
Copyright Lolita Petit et al., 2016; Published by Mary Ann Liebert, Inc.Distribution License
http://creativecommons.org/licenses/by-nc/4.0/ae974a485f413a2113503eed53cd6c53
10.1089/hum.2016.040
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright Lolita Petit et al., 2016; Published by Mary Ann Liebert, Inc.

